US MedTech company focused on neuromodulation.
Axonics Modulation Technologies developed a novel and best-in-class sacral neuromodulation (SNM) system for the treatment of overactive bladder (OAB) and fecal incontinence. Axonics’ r-SNM is small (3cc), fully implantable, rechargeable, MRI compatible andworks in the body for up to 15 years. Axonics has CE Mark, FDA approval and is ramping sales throughout the US and Europe.
Axonics is now publicly listed on the NASDAQ under the ticker symbol AXNX.